{"id":12078,"date":"2025-03-13T22:44:11","date_gmt":"2025-03-13T21:44:11","guid":{"rendered":"https:\/\/valintermed.com\/?p=12078"},"modified":"2025-03-13T22:44:11","modified_gmt":"2025-03-13T21:44:11","slug":"mioklonicheskaya-epilepsiya-svyazannaya-s-rvanymi-krasnymi-voloknami","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/myoclonic-epilepsy-associated-with-red-hair\/","title":{"rendered":"Myoclonic epilepsy associated with ragged red fibers"},"content":{"rendered":"<div class=\"fpm_start\"><\/div>\n<p>Myoclonic epilepsy associated with ragged red fibers is a rare neurological syndrome characterized by the occurrence of myoclonic jerks and seizures caused by metabolic disorders and insufficient energy metabolism in neurons. This condition is closely associated with mitochondrial diseases, in particular with mutations in mitochondrial genes, which leads to damage and dysfunction of neurons. Myoclonic epilepsies usually occur in children and adolescents and have characteristic clinical manifestations such as uncontrolled muscle contractions and epileptic seizures, which significantly reduces the quality of life of patients and requires a comprehensive approach to diagnosis and treatment.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-flat ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Content<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 eztoc-toggle-hide-by-default' ><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/myoclonic-epilepsy-associated-with-red-hair\/#%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\" >History of the disease and interesting historical facts<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/myoclonic-epilepsy-associated-with-red-hair\/#%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F\" >Epidemiology<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/myoclonic-epilepsy-associated-with-red-hair\/#%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%BC%D1%83_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8E\" >Genetic predisposition to this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/myoclonic-epilepsy-associated-with-red-hair\/#%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Risk factors for the development of this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/myoclonic-epilepsy-associated-with-red-hair\/#%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Diagnosis of this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/myoclonic-epilepsy-associated-with-red-hair\/#%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5\" >Treatment<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/myoclonic-epilepsy-associated-with-red-hair\/#%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%B4%D0%BB%D1%8F_%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >List of medications used to treat this disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/myoclonic-epilepsy-associated-with-red-hair\/#%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Disease monitoring<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/myoclonic-epilepsy-associated-with-red-hair\/#%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\" >Age-related features of the disease<\/a><\/li><li class='ez-toc-page-1'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/valintermed.com\/en\/medlibrary\/myoclonic-epilepsy-associated-with-red-hair\/#%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B\" >Questions and Answers<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"%D0%98%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%8F_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F_%D0%B8_%D0%B8%D0%BD%D1%82%D0%B5%D1%80%D0%B5%D1%81%D0%BD%D1%8B%D0%B5_%D0%B8%D1%81%D1%82%D0%BE%D1%80%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5_%D1%84%D0%B0%D0%BA%D1%82%D1%8B\"><\/span>History of the disease and interesting historical facts<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Myoclonic epilepsy associated with ragged red fibers was first described in 1997, when researchers found a link between mitochondrial disorders and epileptic seizures. In 2004, the gene responsible for this disorder was identified, which opened up new horizons in understanding the pathogenesis of myoclonic epilepsy. Interestingly, early descriptions of myoclonus were found in ancient medical texts, but the link with mitochondrial disorders was established only recently. Experts note that advances in genetic diagnostics and neuroimaging have led to a more accurate understanding of the mechanisms that influence the occurrence of this form of epilepsy.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%AD%D0%BF%D0%B8%D0%B4%D0%B5%D0%BC%D0%B8%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%8F\"><\/span>Epidemiology<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Data on the prevalence of myoclonic epilepsy associated with ragged red fibers are limited due to the rarity of the disease. According to recent epidemiological studies, the prevalence is between 1 and 4 cases per 100,000 population. The disease most often begins in childhood or adolescence, which makes it especially relevant for pediatric neurology. The work of Martinz et al. confirmed that individuals with certain mitochondrial mutations have a significantly higher risk of developing epilepsy, which serves as a basis for genetic testing in patients with severe neurological symptoms.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%93%D0%B5%D0%BD%D0%B5%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B0%D1%8F_%D0%BF%D1%80%D0%B5%D0%B4%D1%80%D0%B0%D1%81%D0%BF%D0%BE%D0%BB%D0%BE%D0%B6%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D1%8C_%D0%BA_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%BC%D1%83_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8E\"><\/span>Genetic predisposition to this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Myoclonic epilepsy associated with ragged red fibers is of particular interest to geneticists because its development is influenced by mutations in specific mitochondrial genes. The main genes involved include:<\/p>\n<ul>\n<li><strong>MT-TL1<\/strong> \u2014 a gene encoding tRNA for leucine, mutations in which can lead to disruption of protein synthesis in mitochondria.<\/li>\n<li><strong>MT-ATP6<\/strong> \u2014 a gene associated with ATP synthesis, its abnormalities lead to a decrease in the energy supply of neurons.<\/li>\n<li><strong>POLG<\/strong> \u2014 a gene responsible for the replication of mitochondrial DNA, which can cause mitochondrial dysfunction.<\/li>\n<\/ul>\n<p>There is evidence of a high degree of heritability of the disease, which makes it an important object of study in the field of genetic medicine. Specialized tests can identify a predisposition to myoclonic epilepsy and predict its development in potential patients.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A4%D0%B0%D0%BA%D1%82%D0%BE%D1%80%D1%8B_%D1%80%D0%B8%D1%81%D0%BA%D0%B0_%D0%B2%D0%BE%D0%B7%D0%BD%D0%B8%D0%BA%D0%BD%D0%BE%D0%B2%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Risk factors for the development of this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>There are a number of risk factors that contribute to the development of myoclonic epilepsy associated with ragged red fibers. These include:<\/p>\n<ul>\n<li><strong>Heredity<\/strong> - a family history of myoclonic epilepsy increases the likelihood of the disease.<\/li>\n<li><strong>Metabolic disorders<\/strong> - pre-existing energy metabolism disorders may worsen the condition.<\/li>\n<li><strong>Environmental factors<\/strong> - exposure to toxic chemicals and radiation.<\/li>\n<li><strong>Infectious diseases<\/strong> - some viral infections can contribute to the activation of epileptic activity.<\/li>\n<li><strong>Stress<\/strong> - psycho-emotional stress can cause an exacerbation of symptoms.<\/li>\n<\/ul>\n<p>It is important to note that these factors are not direct causes, but may contribute to modulation of disease manifestations.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%94%D0%B8%D0%B0%D0%B3%D0%BD%D0%BE%D1%81%D1%82%D0%B8%D0%BA%D0%B0_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Diagnosis of this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Diagnosis of myoclonic epilepsy associated with ragged red fibers is based on a comprehensive approach, including:<\/p>\n<ul>\n<li><strong>Main symptoms<\/strong> - involuntary myoclonic jerks, convulsions, neurological disorders.<\/li>\n<li><strong>Laboratory research<\/strong> - lactate level tests, as well as genetic testing methods to identify mutations.<\/li>\n<li><strong>Radiological examinations<\/strong> \u2014 MRI, which allows us to assess structural changes in the brain.<\/li>\n<li><strong>Other types of diagnostics<\/strong> - electroencephalography to record epileptic activity.<\/li>\n<li><strong>Differential diagnosis<\/strong> \u2014 It is important to rule out other causes of myoclonus, such as other types of epilepsy and neurodegenerative diseases.<\/li>\n<\/ul>\n<p>This multi-level diagnostics allows for an accurate diagnosis and adequate treatment.<\/p><script data-noptimize=\"\" data-wpfc-render=\"false\">\nfpm_start( \"true\" );\n<\/script>\n\n<h2><span class=\"ez-toc-section\" id=\"%D0%9B%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D0%B5\"><\/span>Treatment<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Treatment of myoclonic epilepsy involves a multifaceted approach consisting of:<\/p>\n<ul>\n<li><strong>General treatment<\/strong> - lifestyle changes, adherence to sleep and rest regimen, the need for physical activity.<\/li>\n<li><strong>Pharmacological treatment<\/strong> - use of antiepileptic drugs such as valproic acid, levetiracetam and clonazepam.<\/li>\n<li><strong>Surgical treatment<\/strong> \u2014 in severe cases, surgical intervention aimed at removing foci of epileptic activity is possible.<\/li>\n<li><strong>Other types of treatment<\/strong> - physiotherapy and psychological support aimed at improving the quality of life.<\/li>\n<\/ul>\n<p>It is important to take an individual approach to each patient, taking into account his condition and needs.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%A1%D0%BF%D0%B8%D1%81%D0%BE%D0%BA_%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2_%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D1%8F%D0%B5%D0%BC%D1%8B%D1%85_%D0%B4%D0%BB%D1%8F_%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F_%D0%B4%D0%B0%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>List of medications used to treat this disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Key drugs used in the treatment of myoclonic epilepsy include:<\/p>\n<ul>\n<li><strong>Valproic acid<\/strong> \u2014 the main antiepileptic drug.<\/li>\n<li><strong>Levetiracetam<\/strong> \u2014 the drug of choice for the control of myoclonus.<\/li>\n<li><strong>Clonazepam<\/strong> - in case of resistance to other medications.<\/li>\n<li><strong>Retigabine<\/strong> - is used in certain clinical cases.<\/li>\n<li><strong>Topiramate<\/strong> - can be used for combination therapy.<\/li>\n<\/ul>\n<p>Combinations of drugs are selected individually for maximum effectiveness.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%9C%D0%BE%D0%BD%D0%B8%D1%82%D0%BE%D1%80%D0%B8%D0%BD%D0%B3_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Disease monitoring<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Monitoring of patients with myoclonic epilepsy requires regular monitoring of:<\/p>\n<ul>\n<li><strong>Control stages<\/strong> - regular examinations by a neurologist to assess the effectiveness of treatment.<\/li>\n<li><strong>Forecast<\/strong> - depends on the age of onset of the disease and the response to therapy, but complete recovery is rare.<\/li>\n<li><strong>Complications<\/strong> \u2014 cognitive impairment, risk of depression and high degree of disability are possible.<\/li>\n<\/ul>\n<p>Timely detection and elimination of complications play a significant role in the management of this category of patients.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%B7%D1%80%D0%B0%D1%81%D1%82%D0%BD%D1%8B%D0%B5_%D0%BE%D1%81%D0%BE%D0%B1%D0%B5%D0%BD%D0%BD%D0%BE%D1%81%D1%82%D0%B8_%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F\"><\/span>Age-related features of the disease<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The course of myoclonic epilepsy in different age groups has its own differences. In children, the disease manifests itself in more acute and frequent attacks, threatening normal development. Teenagers often suffer from social isolation and depression caused by the disease. Adults, as a rule, have a more persistent type of attacks, but progressive cognitive dysfunction may be observed. In old age, additional complications with treatment may arise due to polypathology and various social factors.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"%D0%92%D0%BE%D0%BF%D1%80%D0%BE%D1%81%D1%8B_%D0%B8_%D0%BE%D1%82%D0%B2%D0%B5%D1%82%D1%8B\"><\/span>Questions and Answers<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>What is myoclonic epilepsy?<\/strong><br \/>\nAnswer: It is a neurological disorder characterized by myoclonic seizures associated with mitochondrial abnormalities.<\/li>\n<li><strong>How is this disease diagnosed?<\/strong><br \/>\nAnswer: Diagnosis includes clinical symptoms, laboratory tests and neuroimaging.<\/li>\n<li><strong>What treatment methods exist?<\/strong><br \/>\nAnswer: Treatment includes drug therapy, surgery, and lifestyle changes.<\/li>\n<li><strong>What medications are used for treatment?<\/strong><br \/>\nAnswer: The main drugs are valproic acid, levetiracetam, clonazepam and others.<\/li>\n<li><strong>What is the prognosis for patients with myoclonic epilepsy?<\/strong><br \/>\nAnswer: The prognosis varies, but complete recovery is rare; early treatment can improve quality of life.<\/li>\n<\/ul>\n<div class=\"fpm_end\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Ragged red fiber myoclonic epilepsy is a rare neurological syndrome characterized by myoclonic jerks and seizures caused by<\/p>","protected":false},"author":1,"featured_media":20806,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[298],"tags":[],"class_list":["post-12078","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medlibrary"],"_links":{"self":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/12078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/comments?post=12078"}],"version-history":[{"count":1,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/12078\/revisions"}],"predecessor-version":[{"id":15042,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/posts\/12078\/revisions\/15042"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/media\/20806"}],"wp:attachment":[{"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/media?parent=12078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/categories?post=12078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/valintermed.com\/en\/wp-json\/wp\/v2\/tags?post=12078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}